Benzinga··Bamboo WorksKailera's 63% IPO Surge Validates Chinese Pharma 'NewCo' Spinoff Strategy
Kailera Therapeutics surged 63% on Nasdaq debut as weight-loss drug spinoff from Hengrui Pharma, raising $625M and validating the 'NewCo' model for Chinese pharmaceutical companies.
LLYNVOGILDJHPCYKLRAIPOGLP-1 drugs